Friday, July 10, 2026

pharma · Kidney Dysfunction · Obesity

LianBio

Jian Li is a pharma organization headquartered in CN. Primary therapeutic focus areas include Kidney Dysfunction, Obesity, Fibrosis, Ebola Virus Disease, Bladder Cancer. NovaPharmaNews links 28 clinical program(s), 0 dru

CN HQ
2019 Founded
47 Employees
NMPA registrant Type
Company details
Status
Public
HQ
CN
Founded
2019
Employees
47
Programs
28
Drugs
40
Patents
0
Clinical program

626

Phase 1 · small molecule · Healthy Subjects (HS)

626 for Healthy Subjects (HS) is a Phase 1 program (small_molecule) at Jian Li with 1 ClinicalTrials.gov record(s).

← All Jian Li projects Phase 1 small molecule active

Internal code SSGJ-626-HV-I-01

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Jian Li
Phase
Phase 1
Modality
small_molecule
Indication
Healthy Subjects (HS)
Status
active
Trials
1

Clinical trials